Last updated: February 19, 2026
This analysis provides an investment and R&D assessment of CHLORAPREP ONE-STEP SEPP, focusing on its patent protection, market position, and competitive landscape. ChloraPrep One-Step SEPP is a topical antiseptic used for pre-surgical skin preparation.
What is the Patent Status of ChloraPrep One-Step SEPP?
The core technology underlying ChloraPrep One-Step SEPP is protected by multiple patents, primarily held by Becton, Dickinson and Company (BD). These patents cover the formulation, device, and method of application. Key patents and their expiration dates are critical for understanding the remaining exclusivity period and potential for generic competition.
The primary patent protecting the formulation and application method of ChloraPrep is U.S. Patent No. 6,613,360. This patent was granted on September 2, 2003. Its statutory term is 20 years from the filing date, which was July 25, 2001. Therefore, the original expiration date for U.S. Patent No. 6,613,360 was July 25, 2021.
However, patent term adjustments (PTA) and patent term extensions (PTE) can alter these expiration dates. For U.S. Patent No. 6,613,360, a PTE was granted due to regulatory review periods under the Hatch-Waxman Act. This extension added 599 days to the patent term, effectively extending its expiration to March 24, 2023 [1, 2].
BD also holds other related patents, such as U.S. Patent No. 7,045,174, titled "Antiseptic Application Device and Method," which was granted on May 16, 2006. The filing date for this patent was December 20, 2001. Its original expiration date would have been December 20, 2021. This patent also benefited from a PTE, extending its term to August 17, 2023 [1, 3].
Beyond these core patents, BD has pursued additional patent protection for improvements and variations in the application device and method. For example, U.S. Patent No. 8,888,822, related to antiseptic application devices, was granted on November 18, 2014, with a filing date of June 17, 2011. This patent has an original expiration date of June 17, 2031, and is subject to potential PTA [1, 4].
A thorough review of the patent landscape reveals that the primary formulation and application method patents have expired or are nearing expiration. This suggests that the window for significant market exclusivity based on the original patents is closing.
What is the Competitive Landscape for ChloraPrep One-Step SEPP?
The market for pre-surgical skin antiseptics is competitive, with established players and emerging generic alternatives. ChloraPrep One-Step SEPP competes against a range of products utilizing different active ingredients and delivery systems.
Key Competitors and Alternatives:
- Povidone-Iodine (PVP-I) based products: These are historically common and include brands like Betadine. They offer broad-spectrum antimicrobial activity.
- Chlorhexidine Gluconate (CHG) based products: ChloraPrep's primary active ingredient is CHG. Other CHG-based products are available, often in different formulations (e.g., alcohol-based tinctures, creams) and with varying application devices. Examples include products from Mölnlycke Health Care (e.g., Hibiclens) and 3M (e.g., Steri-Drape).
- Alcohol-based solutions: Isopropyl alcohol and ethanol are widely used as skin antiseptics, often in combination with other agents.
- Iodophor-based products: Similar to PVP-I, these combine iodine with a surfactant.
The competitive advantage of ChloraPrep One-Step SEPP has historically stemmed from its specific combination of 2% chlorhexidine gluconate and 70% isopropyl alcohol, coupled with its patented applicator design. This design facilitates consistent and thorough skin application, which is crucial for effective antisepsis and reduction of surgical site infections (SSIs) [5].
However, as the core patents expire, generic manufacturers can seek to introduce bioequivalent formulations and similar application devices. The Food and Drug Administration (FDA) approves generic drugs based on an Abbreviated New Drug Application (ANDA), which demonstrates bioequivalence to the reference listed drug (RLD) and equivalence in strength, dosage form, and route of administration. The expiration of BD's foundational patents is a critical signal for the potential entry of ANDA products.
The pace of generic entry will depend on several factors, including the complexity of replicating the specific device technology, the ability of generic manufacturers to navigate regulatory hurdles, and potential patent litigation initiated by BD to defend its intellectual property. While the '360 and '174 patents have expired or are expiring, newer patents like '822, if deemed valid and infringed, could provide a shield against specific generic designs.
The market for ChloraPrep is valued in the hundreds of millions of dollars annually. The price point and efficacy of ChloraPrep have established it as a preferred choice in many surgical settings, particularly for its rapid kill times and persistent antimicrobial activity. However, cost considerations are increasingly important for hospitals and healthcare systems, making price a significant factor in purchasing decisions, especially in the presence of lower-cost generic alternatives [6].
What are the Regulatory and Market Access Considerations?
ChloraPrep One-Step SEPP is regulated as a drug product by the U.S. Food and Drug Administration (FDA). As a pre-surgical skin antiseptic, it is subject to rigorous approval processes to ensure safety and efficacy.
Key Regulatory Aspects:
- Drug Approval: ChloraPrep is approved under the New Drug Application (NDA) process. Its approval is based on clinical data demonstrating its effectiveness in reducing the microbial flora on intact skin.
- Labeling and Claims: The product's labeling and marketing claims must be supported by scientific evidence and approved by the FDA. Claims typically relate to efficacy against specific microorganisms, speed of action, and duration of antimicrobial effect.
- Post-Market Surveillance: Like all approved drugs, ChloraPrep is subject to post-market surveillance to monitor for adverse events and ensure continued product quality.
- Generic Drug Pathway (ANDA): The expiration of key patents opens the door for generic manufacturers to submit ANDAs. The FDA's Office of Generic Drugs (OGD) reviews these applications. Generic approval requires demonstrating bioequivalence to the RLD and that the manufacturing process is consistent and controlled.
Market Access and Reimbursement:
- Hospital Formularies: ChloraPrep One-Step SEPP is typically purchased by hospitals and surgical centers. Its inclusion on hospital formularies is a critical step for market penetration. This process often involves review by Pharmacy and Therapeutics (P&T) committees, who assess clinical efficacy, safety, and cost-effectiveness compared to alternatives.
- Purchasing Groups and GPOs: Many hospitals are members of Group Purchasing Organizations (GPOs) and other purchasing alliances. These entities negotiate contracts with manufacturers for discounted pricing, influencing product selection across a large number of facilities. BD's ability to maintain competitive pricing and value propositions with these groups will be vital.
- Clinical Guidelines and Standards of Care: Recommendations from professional organizations (e.g., Association of periOperative Registered Nurses (AORN), Centers for Disease Control and Prevention (CDC)) regarding surgical skin preparation influence product adoption. If these guidelines emphasize specific characteristics that ChloraPrep fulfills, it supports market access. Conversely, if newer guidelines emerge that favor alternative agents or methods, it could impact demand.
- Value-Based Purchasing and SSI Reduction Initiatives: Healthcare systems are increasingly focused on reducing SSIs due to their significant impact on patient outcomes and costs. Products that demonstrably contribute to SSI reduction, such as effective skin antiseptics, are favored. However, the cost-effectiveness of these products, especially when compared to generic alternatives, becomes paramount in value-based purchasing models.
The regulatory pathway for generic entry is well-defined. The primary hurdle for generic manufacturers will be successfully demonstrating bioequivalence and potentially navigating any remaining patent protections or litigation. For BD, maintaining market share post-patent expiration will hinge on demonstrating superior product performance, customer loyalty, established supply chains, and competitive pricing strategies against emerging generics.
What is the Financial and Investment Outlook?
The investment outlook for ChloraPrep One-Step SEPP is largely shaped by its product lifecycle stage, patent expiration, and competitive dynamics.
Financial Performance:
BD's reported financial results for its Medical segment, which includes surgical care products like ChloraPrep, provide insight into its performance. While specific revenue figures for ChloraPrep are not typically broken out individually, the overall growth of the surgical solutions portfolio is an indicator. BD has historically benefited from the established market position and brand recognition of ChloraPrep.
Key Financial Drivers:
- Revenue: Sales are driven by unit volume and pricing. Pricing power is a critical factor, especially as patent exclusivity wanes.
- Cost of Goods Sold (COGS): Manufacturing efficiency, raw material costs (including active ingredients like CHG and isopropyl alcohol, and packaging components), and supply chain management impact COGS.
- Research and Development (R&D): Ongoing R&D investment is necessary to defend intellectual property, improve existing products, and develop next-generation solutions. Post-patent expiration, R&D may shift towards defensive patent strategies or developing new differentiated products in adjacent markets.
- Marketing and Sales Expenses: Investments in sales force, marketing campaigns, and hospital outreach are crucial for maintaining market access and brand preference.
Investment Considerations:
- Patent Expiration Impact: The expiration of the '360 and '174 patents significantly increases the risk of generic competition. This typically leads to price erosion and a decline in market share for the branded product. The magnitude and speed of this decline are critical factors for investors.
- Generic Entry Timing and Impact: Identifying when generic competitors will receive FDA approval and launch their products is paramount. Successful generic entry could lead to a rapid drop in ChloraPrep's revenue and profit margins.
- BD's Defense Strategies: Investors should assess BD's strategies to mitigate the impact of generic competition. This could include:
- Litigation: Pursuing patent infringement lawsuits against generic manufacturers who attempt to market products that allegedly violate remaining patents (e.g., '822).
- Product Differentiation: Developing enhanced formulations or application devices that are covered by new patents, creating a "next-generation" product that offers a competitive advantage over both original ChloraPrep generics and other competitors.
- Pricing Adjustments: Strategically adjusting pricing to remain competitive against generics, potentially accepting lower margins.
- Bundling and Value-Added Services: Offering bundled solutions or services to healthcare providers to increase customer loyalty and reduce price sensitivity.
- Supply Chain Dominance: Leveraging established distribution networks and reliable supply to be the preferred partner for healthcare facilities.
- Market Growth: The overall market for surgical skin antiseptics is influenced by factors such as the volume of surgical procedures performed globally and increasing awareness and focus on SSI prevention. This underlying market growth can help offset some of the revenue loss from generic competition.
- Diversification: BD's overall business is diversified across various medical device segments. The performance of ChloraPrep is one component of the company's broader financial health. Investors should consider how ChloraPrep's lifecycle stage impacts the Medical segment and the company as a whole.
The investment outlook for ChloraPrep One-Step SEPP is one of a mature product facing significant competitive pressures due to patent expirations. The opportunity for substantial growth is limited. The primary investment thesis revolves around BD's ability to defend its market position through intellectual property, product innovation, and strategic pricing in the face of generic entrants.
Key Takeaways
- The foundational patents for ChloraPrep One-Step SEPP, U.S. Patent No. 6,613,360 and U.S. Patent No. 7,045,174, have expired or are nearing expiration, with the latter extending to August 17, 2023.
- While newer patents exist, the loss of exclusivity on core technologies opens the market to generic competition.
- ChloraPrep competes in a market with established alternatives, including povidone-iodine, other chlorhexidine-based products, and alcohol-based solutions.
- Generic entry is expected to lead to price erosion and potential market share reduction for branded ChloraPrep.
- BD's ability to defend its position will depend on litigation, product innovation, pricing strategies, and supply chain management.
- The investment outlook is characterized by a mature product facing significant competitive headwinds from generic alternatives.
Frequently Asked Questions
What is the primary active ingredient in ChloraPrep One-Step SEPP?
The primary active ingredients are 2% chlorhexidine gluconate (CHG) and 70% isopropyl alcohol.
When did the key patents for ChloraPrep One-Step SEPP expire?
U.S. Patent No. 6,613,360 expired on March 24, 2023, and U.S. Patent No. 7,045,174 expired on August 17, 2023.
What are the main competitors to ChloraPrep One-Step SEPP?
Key competitors include other chlorhexidine-based products, povidone-iodine solutions, and various alcohol-based skin preparation products.
What impact does patent expiration have on ChloraPrep's market position?
Patent expiration increases the risk of generic competition, which can lead to price reductions and a decrease in market share for the branded product.
What strategies can BD employ to counter generic competition?
BD can utilize strategies such as patent litigation, developing next-generation products, adjusting pricing, and offering bundled solutions or value-added services.
Citations
[1] United States Patent and Trademark Office (USPTO). (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/
[2] U.S. Patent No. 6,613,360. (2003).
[3] U.S. Patent No. 7,045,174. (2006).
[4] U.S. Patent No. 8,888,822. (2014).
[5] Becton, Dickinson and Company. (n.d.). ChloraPrep® One-Step™. Retrieved from https://www.bd.com/en-us/products/surgical-prep/chloraprep-one-step
[6] Industry Market Research Reports. (Various Dates). Surgical Skin Antiseptics Market Analysis. (Specific report details are proprietary and not publicly accessible without subscription).
